Medicine & Life Sciences
PCI 32765
100%
Azacitidine
89%
Urinary Bladder Neoplasms
64%
obinutuzumab
57%
eltrombopag
55%
romidepsin
54%
venetoclax
53%
INCB018424
52%
GATA2 Deficiency
46%
Polycythemia Vera
43%
Phase II Clinical Trials
41%
High-Throughput Nucleotide Sequencing
40%
Acute Myeloid Leukemia
40%
Mutation
39%
Maximum Tolerated Dose
39%
Myelodysplastic Syndromes
37%
B-Cell Chronic Lymphocytic Leukemia
35%
Tamoxifen
35%
Progression-Free Survival
33%
Hematopoietic Stem Cells
33%
Vaccination
26%
Therapeutics
23%
Biomarkers
21%
DNA
20%
Drug Therapy
19%
Cell-Free Nucleic Acids
16%
Genes
15%
Neoplasms
15%
Bone Marrow
10%
Alleles
10%
T-Lymphocytes
10%
Histone Deacetylase Inhibitors
9%
Disease Progression
8%
Blood Platelets
8%
Transcriptome
8%
afimoxifene
8%
Recurrence
7%
Safety
7%
Platelet Transfusion
7%
Epidemiology
6%
Vaccines
6%
Oxidative Phosphorylation
6%
Apoptosis
5%
Tumor Lysis Syndrome
5%
Proportional Hazards Models
5%
Survival
5%
Stem Cells
5%
Prospective Studies
5%
Antigens
5%
Thrombocytopenia
5%
Physics & Astronomy
neoplasms
53%
stem cells
34%
transponders
23%
phosphorylation
11%
apoptosis
11%
toxicity
10%
genes
9%
blood
8%
tumors
8%
safety
8%
therapy
8%
proportion
7%
signatures
6%